No Data
No Data
BofA Securities Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $11
Caribou Biosciences Starts Phase 1 Trial for Lupus Drug Candidate
Express News | Reported Earlier, Caribou Biosciences Advances CB-010, CB-011, And CB-012 Programs With Key Clinical Updates Expected In 2025; Cash Position $281M
Caribou Biosciences Initiates Phase 1 Clinical Trials for CB-010 in Lupus and Advances Multiple CAR-T Therapy Programs
Express News | Caribou Biosciences Initiates the CB-010 Gallop Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025
Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025